| VERRICA PHARMACEUTICALS |
| USA |
| Gesundheit |
| US92511W2070 / A41A98 |
| 1NE0 (Frankfurt) / VRCA (NASDAQ) |
| FRA:1NE0, ETR:1NE0, 1NE0:GR, NASDAQ:VRCA |
| - |
| https://verrica.com/ |
|
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and commercializing medications for the treatment of skin diseases in the United States. The company's primary product is YCANTH (VP-102), a drug-device combination featuri..
>Volltext.. |
| 81.41 Mio. EUR |
| 56.7 Mio. EUR |
| 30.82 Mio. EUR |
| -9.67 Mio. EUR |
| -15.49 Mio. EUR |
| -1.39 EUR |
| 1.41 Mio. EUR |
| 26.12 Mio. EUR |
| -15.37 Mio. EUR |
| 1.83 |
| 370.22% |
| 76.64% |
| - |
| - |
| - |
| - |
| VERRICA |
| 03.04.26 |
|